HART
IQ Healthy Hearts ETF
When You Invest, Hearts Benefit
An IQ Dual Impact ETF
INVESTING IN HART AND WITH HEART

Monumental changes happen when we invest in each other and for the greater good. When we look to invite financial gain through wise impact investing while inspiring change in the process.

Developed by IndexIQ, a New York Life Investments company, IQ Healthy Hearts ETF (HART) is a performance-driven ETF comprised of well-known stocks of global companies that contribute to the fight against heart disease or promote healthy lifestyles.

As a historic first for New York Life Investments, and in alignment with the American Heart Association, Inc. (AHA), HART reflects our commitment to serve our communities. It is a goal augmented by New York Life Investments’ support of AHA’s Social Impact Fund,* which aims to tackle the social and economic barriers to health equity. Investing in HART helps to further these ongoing contributions.

HART is the first of several Dual Impact ETFs from IndexIQ created to enhance the potential of investor portfolios while advancing social good.

Heart disease is the #1 cause of death in the U.S.¹

127 million Americans over 20 live with heart disease¹

Heart disease costs the U.S. $216 billion each year¹

As studies show that heart disease is greatly preventable and the global population looks to extend its longevity, we believe that companies which contribute to the fight against heart disease or help promote healthy living will outperform the broader equity market in the future.

Invest in HART and you’re investing in companies that strive to create healthier communities by helping individuals adopt healthier lifestyles that can, in turn, reduce heart disease and its detrimental effects.

HART tracks the IQ CANDRIAM Healthy Hearts Index, which is designed to provide investors exposure to well-known stocks of global companies that:

- Seek to diagnose or treat cardiovascular disease
- Enable people to adopt healthier lifestyles through above-average involvement in healthy food & wellness products
- Provide solutions for people to engage in regular exercise and track their fitness
- Offer access to health education through IT services

As part of a balanced investment portfolio, HART seeks to further the goal of promoting heart health while generating attractive return potential.
HOW HEART HEALTH CAN KEEP YOUR PORTFOLIO BEATING

Heart disease is the leading cause of death worldwide.²

Coupled with an increasingly aging population looking to adopt healthier lifestyles, it’s no surprise that:

- Sectors surrounding heart health are becoming increasingly important
- Treatments for heart disease continue to evolve

Through HART, investors can access the growing trend of health and wellness across multiple sectors, as well as advancements in the treatment of cardiovascular diseases, while also contributing to positive change in the fight against health inequity. HART’s portfolio allocation includes companies such as:

- Multinational consumer electronics manufacturer specializing in mobile devices, personal computers, tablets, and wearables
  Sector: Technology
  Country: United States

- Developer and manufacturer of athletic footwear, apparel, and accessories
  Sector: Consumer Discretionary
  Country: United States

- Multinational packaged food company
  Sector: Consumer Staples
  Country: Switzerland

- Pharmaceutical products manufacturer focused on diabetes care and insulin delivery systems
  Sector: Health Care
  Country: Denmark
The American Heart Association’s Social Impact Fund was established in 2018 as a way to further its mission of promoting heart health. The Fund provides grants or loans to qualified organizations in communities that might otherwise not have access to start-up or growth capital. As a result, these organizations are able to address the economic and social conditions that can affect a person’s health, including social cohesion, employment, education, housing, and food access.

To underscore New York Life Investments’ commitment to promoting better health, New York Life Investments and IndexIQ are donors to and supporters of AHA’s Social Impact Fund.* Investing in HART helps to further these contributions, through which we will be able to help under-resourced communities achieve health equity.

The Threat to Heart Health
Consider that in the United States today:

- 80% of your health is determined by where you live⁶
- 40 million people live without enough food at home⁷
- 1 in 5 children live in food-insecure homes⁸
- 1 in 2 deaths from heart disease, stroke, and type 2 diabetes are linked to a poor diet⁹
- Lower-income neighborhoods tend to lack access to healthy foods and a safe place to exercise¹⁰
IQ DUAL IMPACT ETFs
Investing with a Conscience to Make a Difference

The wisdom of impact investing lies in its innate commitment to doing good, both by possibly generating financial returns and as a vehicle for social and/or environmental good. IndexIQ created our new suite of thematic ETFs, the IQ Dual Impact ETFs, to tackle a variety of social and environmental issues important to you and to everyone. So, you can invest with conscience, as well as purpose.

When you invest in HART and in any of our IQ Dual Impact ETFs, you’re furthering our shared commitment to improving individual lives and our planet. Most of all, IndexIQ is helping you align your investments with your values.

PUT HART IN YOUR PORTFOLIO

Now’s the time to invest in the issues that matter. Now’s the time to diversify your portfolio through the forward-thinking impact investing made possible by IndexIQ and our Dual Impact ETFs.

HART is available on all major trading platforms.
**New York Life Investment Management LLC (NYLIM) and IndexIQ Advisors LLC (IndexIQ) are donors to and supporters of the American Heart Association’s Social Impact Fund and are making a substantial contribution to the Social Impact Fund.**

Shares of the Fund are not sponsored, endorsed or promoted by American Heart Association, Inc. (“AHA”). The Fund’s sponsor, IndexIQ, and its affiliates are donors to and supporters of AHA’s Social Impact Fund and are making a substantial contribution to the Social Impact Fund in connection with AHA’s agreement to license use of its name and trademarks to IndexIQ and its affiliates. AHA makes no representation or warranty, express or implied, to prospective or actual investors in the Fund or to any member of the public regarding the advisability of investing in any financial product, including one seeking to track the Underlying Index, the ability of the Fund to track the performance of the Underlying Index, the ability of the Underlying Index to meet or exceed stock market performance, the suitability of the Fund or the ability of the Underlying Index or Fund to achieve its investment goals. AHA has no obligation or liability in connection with the administration, marketing or trading of shares of the Fund. AHA is not an investment adviser or a fund distributor or service provider. Inclusion of a security within the Underlying Index is not a recommendation by AHA to buy, sell or hold such security, nor is it considered to be investment advice or a guarantee that the investment goals of the Underlying Index will be achieved. AHA does not guarantee the accuracy and/or the completeness of the Underlying Index or any data included therein.

**ABOUT RISK**

Before considering an investment in the Fund, you should understand that you could lose money.

The performance of the Underlying Index and the Fund may deviate from that of the markets the Underlying Index seeks to track due to changes that are reflected in the markets more quickly than the annual rebalancing process can track. Securities in the Underlying Index or the Fund’s portfolio may also underperform in comparison to the general securities markets. When the Fund invests in foreign markets, it will be subject to risk of loss not typically associated with domestic markets. Loss may result because of less foreign government regulation, less public information and less economic, political and social stability. Loss may also result from the imposition of exchange controls, confiscations and other governmental restrictions.

The IQ CANDRIAM Healthy Hearts Index seeks to provide investors with exposure to select companies that are involved in the diagnosis and/or treatment of heart disease, or that provide goods or services that allow people to adopt or maintain a healthy lifestyle. **Principal Risks** - Investors in the Fund should be willing to accept a high degree of volatility in the price of the Fund’s Shares and the possibility of significant losses. As with all investments, you may lose money in the Fund. **New Fund Risk** the Fund is a new fund. As a new fund, there can be no assurance that it will grow to or maintain an economically viable size, in which case it could ultimately liquidate. **Equity Securities Risk** Investments in common stocks and other equity securities are particularly subject to the risk of changes in investors’ perceptions of the financial condition of an issuer, conditions affecting equity markets generally and political and/or economic events. Equity prices may also be particularly sensitive to rising interest rates, as the cost of capital rises and borrowing costs increase. Holders of an issuer’s common stock may be subject to greater risks than holders of its preferred stock and debt securities because common stockholders’ claims are subordinated to those of holders of preferred stocks and debt securities upon the bankruptcy of an issuer. **Large-Capitalization Companies Risk** Large-capitalization companies may be less able than smaller capitalization companies to adapt to changing market conditions. Large-capitalization companies may be more mature and subject to more limited growth potential compared with smaller capitalization companies. During different market cycles, the performance of large-capitalization companies has tracked the overall performance of the broader securities markets. **Small and/or Mid-Capitalization Companies Risk** Small-and mid-capitalization companies may be more vulnerable to adverse general market or economic developments, and their securities may be less liquid and may experience greater price volatility than larger, more established companies. **Foreign Investing Risk** Foreign securities can be subject to greater risks than U.S. investments, including currency fluctuations, less liquid trading markets, greater price volatility, political and economic instability, less publicly available information, and changes in tax or currency laws or monetary policy. These risks are likely to be greater for emerging markets than in developed markets. **Passive Management Risk**. The Fund is not actively managed and instead seeks to track the performance of an Index.

Consider the Fund’s investment objectives, risks, charges and expenses carefully before investing. The prospectus and the statement of additional information include this and other relevant information about the Fund and are available by visiting newyorklifeinvestments.com/eff. Read the prospectus carefully before investing.

“New York Life Investments” is both a service mark, and the common trade name, of certain investment advisors affiliated with New York Life Insurance Company. IndexIQ® is the indirect wholly owned subsidiary of New York Life Investment Management Holdings LLC and serves as the advisor to the IndexIQ EFTs. ALPS Distributors, Inc. (ALPS) is the principal underwriter of the EFTs, and NYLIFE Distributors LLC is a distributor of the EFTs. NYLIFE Distributors LLC is located at 30 Hudson Street, Jersey City, NJ 07302. ALPS Distributors, Inc. is not affiliated with NYLIFE Distributors LLC. NYLIFE Distributors LLC is a Member FINRA/SIPC.


3 Fortune Business Insights, Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type, By Disease Indication, By Distribution Channel and Regional Forecast, 2019–2026. As of Nov. 2019.


